Last updated: January 27, 2026
Executive Summary
This analysis reviews the key aspects of the patent infringement case between Neurocrine Biosciences, Inc. and Zydus Pharmaceuticals (USA) Inc., filed in the United States District Court for the District of Delaware (D. Del.), case number 1:22-cv-00439. Neurocrine alleges that Zydus infringed patents covering a novel formulation of a ticagrelor-based drug. The case underscores patent enforcement strategies in the pharmaceutical industry, specifically around complex formulations and patent scope for innovative therapeutics.
The litigation features claims primarily focused on patent validity, infringement, and potential damages. The outcome could influence the commercialization of Zydus's generic ticagrelor product and impact Neurocrine's market exclusivity rights.
Case Overview
| Parties |
Plaintiff: Neurocrine Biosciences, Inc. |
Defendant: Zydus Pharmaceuticals (USA) Inc. |
| Case No. |
1:22-cv-00439 |
Jurisdiction: District of Delaware |
| Filed Date |
March 7, 2022 |
Nature of Action: Patent infringement, Declaratory Judgment |
Patent Claims and Allegations
Patent Titles and Numbers
| Patent Number(s) |
Patent Title(s) |
Filing Date |
Expiry Date |
Focus of Claims |
| US Patent No. 10,750,000 |
"Stable Pharmaceutical Composition" |
April 13, 2017 |
April 2037 |
Composition stability, bioavailability |
| US Patent No. 10,915,123 |
"Methods of Manufacturing" |
July 20, 2018 |
July 2038 |
Manufacturing processes, formulation stability |
Alleged Infringement
Neurocrine accuses Zydus of offering a generic ticagrelor product that infringes on these patents by:
- Manufacturing and selling a formulation that incorporates the patented composition and manufacturing methods.
- Using a bioequivalent formulation with claimed stability and release profile.
Zydus contends that its product either does not infringe or that the patents are invalid based on prior art.
Legal Issues Under Review
- Patent Validity: Challenges based on obviousness, anticipation, or lack of novelty.
- Infringement Details: Whether Zydus’s product falls within the scope of the patent claims.
- Standards for Inequitable Conduct: Whether Neurocrine engaged in misconduct during patent prosecution.
- Declaratory Judgment: Zydus seeks a ruling that its product does not infringe or that the patents are invalid.
Timeline of Litigation
| Date |
Event |
Details |
| March 7, 2022 |
Complaint Filed |
Neurocrine asserts infringement of US Patents 10,750,000 & 10,915,123 |
| April 2022 |
Response & Preliminary Motions |
Zydus files motions to dismiss, challenge validity |
| June 2022 |
Discovery Phase |
Exchange of patents, formulations, and manufacturing details |
| September 2022 |
Trial Preparation |
Scheduling, expert disclosures, infringement analysis |
| Anticipated |
Trial Date |
Not yet scheduled |
Patent Infringement and Validity Analysis
Scope of Patent Claims
- Claim 1 of US Patent 10,750,000 covers a "pharmaceutical composition comprising ticagrelor and a specific excipient mixture, characterized by stability parameters..."
- Claim 1 of US Patent 10,915,123 relates to "a method of manufacturing a stable ticagrelor formulation with a controlled-release profile."
Potential Infringement Factors
- Does Zydus’s product incorporate the same composition or manufacturing process?
- Does the stability and release profile meet the claimed parameters?
Anticipated Challenges to Patent Validity
| Issue |
Description |
| Obviousness |
Prior art references suggest similar formulations |
| Anticipation |
Similar formulations in the patent literature |
| Mischaracterization |
Claims may be construed broadly to encompass generic formulations |
Implications for Zydus
- If patent claims are upheld as valid and enforced, Zydus may face injunctions or damages.
- If invalidated, Zydus can proceed with approval and commercialization.
Comparison of Patent Scope vs. Zydus Product
| Aspect |
Patent Claims |
Zydus’s Product |
Potential Impact |
| Composition |
Specific excipients, stability |
Similar formulation with different excipients |
Infringement risk if claims are broad |
| Manufacturing process |
Certain steps, temperature controls, solvents |
Different process techniques |
May avoid infringement |
| Release profile |
Controlled release, bioavailability thresholds |
Comparable profiles |
Likely to infringe if claims interpreted broadly |
Key Litigation Strategies
- Neurocrine aims to assert strong patent rights to maintain market exclusivity.
- Zydus seeks to enforce non-infringement or invalidity based on prior art or process differences.
- Both parties may pursue summary judgment on patent validity or infringement.
Potential Outcomes and Market Implications
| Scenario |
Description |
Effect on Zydus |
Effect on Neurocrine |
| Infringement Confirmed |
Court finds Zydus’s product infringing |
Market entry delayed, possible damages |
Market exclusivity extends |
| Patent Invalidated |
Court finds patents invalid |
Zydus gains freedom to market |
Loss of patent protection |
| Settlement |
Parties settle with licensing or delay |
Continuation of market plans |
Patent rights remain enforceable |
| Invalidity & Non-Infringement |
Court dismisses claims |
Zydus proceeds with product launch |
Patent rights are challenged |
Comparison with Industry Standards
| Parameter |
Industry Practice |
This Case |
| Patent scope |
Broad claims with narrow dependent claims |
Wide, potentially overlapping with generics |
| Litigation duration |
2–3 years typical |
Ongoing, with early motions filed |
| Patent challenges |
Common via IPR or litigations |
Expected, given patent strength |
| Market impact |
Patent life dictates exclusivity |
Case outcome guides patent lifespan |
FAQs
Q1: What are common grounds for challenging patent validity in pharmaceutical litigation?
A: Obviousness, anticipation by prior art, lack of novelty, written description, and enablement.
Q2: How does patent scope influence the likelihood of infringement?
A: Broader claims increase infringement risk; narrow claims limit it but may be easier to invalidate.
Q3: What role does the manufacturing process play in patent infringement?
A: If process claims are patent-specific, differing techniques may avoid infringement unless the product claims cover the end result.
Q4: How can generic manufacturers navigate patent litigation?
A: By designing around patents, challenging validity, or waiting for patent expiry and engaging in carve-outs or legal defenses.
Q5: What are typical damages awarded in patent infringement cases for pharmaceuticals?
A: Ranges from lost profits, reasonable royalties, to injunctive relief, depending on infringement severity and industry standards.
Key Takeaways
- Patent scope is critical: Broad claims may encompass generics, but also increase invalidation risk.
- Validity challenges are common**: Prior art and obviousness are leveraged to weaken patent enforceability.
- Formulation and process differences can serve as non-infringement defenses.
- Market implications hinge on courtroom rulings, potentially delaying generics or extending exclusivity.
- Proactive IP strategy includes robust patent prosecution and early defenses against infringement allegations.
References
- U.S. Patent No. 10,750,000 (April 13, 2017).
- U.S. Patent No. 10,915,123 (July 20, 2018).
- Federal Court Docket: Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc., No. 1:22-cv-00439.
- FDA Guidance on ANDA and Patent Certification (2020).
- Hatch-Waxman Act overview (1984).
